Literature DB >> 2412921

Antibodies to the cytoskeleton components and other autoantibodies in inflammatory bowel disease.

D Zauli, C Crespi, P Dall'Amore, F B Bianchi, E Pisi.   

Abstract

A high prevalence of antibodies to cytoskeleton components (anti-CYTO) and of anti-smooth muscle (SMA) and antinuclear (ANA) antibodies has been found in inflammatory bowel disease (IBD). In particular, a significant correlation has been documented between anti-CYTO and activity of the disease in ulcerative colitis and anti-fibroblast intermediate filaments (anti-vimentin) antibodies and Crohn's disease. The antibodies are detectable in the three major immunoglobulin classes, including IgA. While titres of anti-CYTO did not exceed 1:40, ANA and SMA were of high titres (up to 1:1,280). Antibodies to epithelial cells intermediate filaments (anti-cytokeratin) were detected only occasionally. The significance of these findings in IBD is discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2412921     DOI: 10.1159/000199232

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  10 in total

1.  IgG subclass distribution in serum and rectal mucosa of monozygotic twins with or without inflammatory bowel disease.

Authors:  L Helgeland; C Tysk; G Järnerot; K Kett; E Lindberg; D Danielsson; S N Andersen; P Brandtzaeg
Journal:  Gut       Date:  1992-10       Impact factor: 23.059

2.  Anti-actin IgA antibodies in severe coeliac disease.

Authors:  A Granito; P Muratori; F Cassani; G Pappas; L Muratori; D Agostinelli; L Veronesi; R Bortolotti; N Petrolini; F B Bianchi; U Volta
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

3.  Antinuclear autoantibodies in patients with inflammatory bowel disease. High prevalence in first-degree relatives.

Authors:  C Folwaczny; N Noehl; S P Endres; W Heldwein; K Loeschke; H Fricke
Journal:  Dig Dis Sci       Date:  1997-08       Impact factor: 3.199

4.  Autoimmunity in chronic liver disease caused by hepatitis delta virus.

Authors:  D Zauli; C Crespi; F B Bianchi; A Craxi; E Pisi
Journal:  J Clin Pathol       Date:  1986-08       Impact factor: 3.411

5.  Detection of anti-cytokeratin 8 antibody in the serum of patients with cryptogenic fibrosing alveolitis and pulmonary fibrosis associated with collagen vascular disorders.

Authors:  N Dobashi; J Fujita; Y Ohtsuki; I Yamadori; T Yoshinouchi; T Kamei; M Tokuda; S Hojo; H Okada; J Takahara
Journal:  Thorax       Date:  1998-11       Impact factor: 9.139

6.  IgA anti-actin antibodies in children with celiac disease: comparison of immunofluorescence with Elisa assay in predicting severe intestinal damage.

Authors:  Elena Bazzigaluppi; Barbara Parma; Giulia M Tronconi; Patrizia Corsin; Luca Albarello; Stefano Mora; Graziano Barera
Journal:  Ital J Pediatr       Date:  2010-03-18       Impact factor: 2.638

7.  Antibodies in cerebral cavernous malformations react with cytoskeleton autoantigens in the lesional milieu.

Authors:  Dongdong Zhang; Andrew J Kinloch; Abhinav Srinath; Robert Shenkar; Romuald Girard; Rhonda Lightle; Thomas Moore; Janne Koskimäki; Azam Mohsin; Julián Carrión-Penagos; Sharbel Romanos; Le Shen; Marcus R Clark; Changbin Shi; Issam A Awad
Journal:  J Autoimmun       Date:  2020-04-30       Impact factor: 7.094

8.  Quantitation of autoantibodies to cytokeratins in sera from patients with squamous cell carcinoma of the oesophagus.

Authors:  R B Veale; A L Thornley; E Scott; A Antoni; I Segal
Journal:  Br J Cancer       Date:  1988-12       Impact factor: 7.640

Review 9.  Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies.

Authors:  Michael Mahler; Pier-Luigi Meroni; Xavier Bossuyt; Marvin J Fritzler
Journal:  J Immunol Res       Date:  2014-04-27       Impact factor: 4.818

10.  Prevalence of antinuclear antibodies in inflammatory bowel disease and seroconversion after biological therapy.

Authors:  María José García; Juan Carlos Rodríguez-Duque; Marta Pascual; Coral Rivas; Beatriz Castro; Sandra Raso; Marcos López-Hoyos; María Teresa Arias-Loste; Montserrat Rivero
Journal:  Therap Adv Gastroenterol       Date:  2022-03-02       Impact factor: 4.409

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.